Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges
Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/3/366 |
| _version_ | 1827626663764033536 |
|---|---|
| author | Miguel Olivas-Aguirre Liliana Torres-López Kathya Villatoro-Gómez Sonia Mayra Perez-Tapia Igor Pottosin Oxana Dobrovinskaya |
| author_facet | Miguel Olivas-Aguirre Liliana Torres-López Kathya Villatoro-Gómez Sonia Mayra Perez-Tapia Igor Pottosin Oxana Dobrovinskaya |
| author_sort | Miguel Olivas-Aguirre |
| collection | DOAJ |
| description | Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD’s interaction with conventional anticancer drugs; (d) CBD’s potential in palliative care for cancer patients; (e) CBD’s tolerability and reported side effects; (f) CBD delivery for anticancer treatment. |
| first_indexed | 2024-03-09T13:00:44Z |
| format | Article |
| id | doaj.art-6624975dd94b45e98e3211d949a6189d |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T13:00:44Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-6624975dd94b45e98e3211d949a6189d2023-11-30T21:55:05ZengMDPI AGPharmaceuticals1424-82472022-03-0115336610.3390/ph15030366Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and ChallengesMiguel Olivas-Aguirre0Liliana Torres-López1Kathya Villatoro-Gómez2Sonia Mayra Perez-Tapia3Igor Pottosin4Oxana Dobrovinskaya5Laboratory of Immunobiology and Ionic Transport Regulation, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colima 28045, MexicoLaboratory of Immunobiology and Ionic Transport Regulation, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colima 28045, MexicoLaboratory of Immunobiology and Ionic Transport Regulation, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colima 28045, MexicoUnidad de Desarrollo e Investigación en Bioterapeúticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (ENCB-IPN), Mexico City 11340, MexicoLaboratory of Immunobiology and Ionic Transport Regulation, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colima 28045, MexicoLaboratory of Immunobiology and Ionic Transport Regulation, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colima 28045, MexicoCannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD’s interaction with conventional anticancer drugs; (d) CBD’s potential in palliative care for cancer patients; (e) CBD’s tolerability and reported side effects; (f) CBD delivery for anticancer treatment.https://www.mdpi.com/1424-8247/15/3/366anticancer activityanticancer treatmentadverse effectscannabidiolclinical trialsdrug delivery |
| spellingShingle | Miguel Olivas-Aguirre Liliana Torres-López Kathya Villatoro-Gómez Sonia Mayra Perez-Tapia Igor Pottosin Oxana Dobrovinskaya Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges Pharmaceuticals anticancer activity anticancer treatment adverse effects cannabidiol clinical trials drug delivery |
| title | Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges |
| title_full | Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges |
| title_fullStr | Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges |
| title_full_unstemmed | Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges |
| title_short | Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges |
| title_sort | cannabidiol on the path from the lab to the cancer patient opportunities and challenges |
| topic | anticancer activity anticancer treatment adverse effects cannabidiol clinical trials drug delivery |
| url | https://www.mdpi.com/1424-8247/15/3/366 |
| work_keys_str_mv | AT miguelolivasaguirre cannabidiolonthepathfromthelabtothecancerpatientopportunitiesandchallenges AT lilianatorreslopez cannabidiolonthepathfromthelabtothecancerpatientopportunitiesandchallenges AT kathyavillatorogomez cannabidiolonthepathfromthelabtothecancerpatientopportunitiesandchallenges AT soniamayrapereztapia cannabidiolonthepathfromthelabtothecancerpatientopportunitiesandchallenges AT igorpottosin cannabidiolonthepathfromthelabtothecancerpatientopportunitiesandchallenges AT oxanadobrovinskaya cannabidiolonthepathfromthelabtothecancerpatientopportunitiesandchallenges |